—
C+
C+ The full Closelook — membership. Open the C+ overview

ResMed Inc (RMD) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — ResMed Inc

RMD in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
ResMed makes cloud-connected medical devices for diagnosing and treating sleep and breathing disorders, alongside software for home and residential care providers. Its device range includes portable sleep monitors, remote-monitoring platforms such as AirView, and patient support apps such as myAir. Its software arm, built from brands including Brightree, HealthcareFirst, MatrixCare and MEDIFOX DAN, gives home health, hospice and senior-care organisations tools for records, billing and analytics. The company runs two segments, Sleep and Breathing Health, and Residential Care Software, and is based in San Diego, selling to clinics, hospitals and homes worldwide.
Where it sits in the stack
ResMed holds no seat in our AI build-out index; within our wider universe it sits in Healthcare, in the medical instruments and supplies sleeve, covering connected diagnostic devices and care-management software rather than any compute or chip layer.
Who it is priced against
Closelook's peer group does not name a comparison set for ResMed; the widely cited rival in sleep and respiratory devices is Koninklijke Philips.
Why Closelook tracks it
ResMed holds a seat in the S&P 500 but carries no seat in our AI build-out index and no Closelook score; the diary has not yet quoted or covered it in any edition.
What the diary watches
The diary watches whether the growing weight of software and remote-monitoring revenue changes how the business compares with its device-only history.

ResMed Inc (RMD) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for RMD, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 2 analyst actions on the wire · latest: upgrade by RBC Capital, 2026-09-15

The Street on this name

Analyst actions and the latest print for RMD from the Closelook wires — third-party opinions on the record, not our readings.

  • Upgrade RBC Capital — Sector Perform → Outperform Upgraded to Outperform from Sector Perform 2026-09-15
  • Price target KeyBanc — target 267 from 255 Target raised to $267 from $255 (+11.1% to spot) 2026-08-31

2 actions on the analyst wire since 2026-08-13: 1 upgrade, 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Medical Instruments & Supplies · United States · 8 names with week and year-to-date

Peer group

Medical Instruments & Supplies · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against RMD on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 1.09%, quarterly · last 0.66 USD on 2026-08-20

Dividends and capital return

What RMD pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 2.46 USD per share · a 1.09% yield on the 2026-09-18 close 4 distributions, paid quarterly 2026-09-18
  • Change on the year +12.3% against the prior twelve months prior twelve months 2.19 USD per share
  • Last distribution 0.66 USD per share as the price series records it, within days of the ex-date 2026-08-20
  • By calendar year 2023: 0.48 USD (partial) · 2024: 2.02 USD · 2025: 2.26 USD · 2026: 1.86 USD to date first distribution recorded in the three-year window: 2023-11-08

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is ResMed Inc (RMD)?

ResMed Inc trades as RMD on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-19.

Is RMD in a Closelook index?

Not currently — ResMed Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does RMD trade against its moving averages?

Recovery attempt under the 200-day: Trades +3.1% vs the 50-day and -0.7% vs the 200-day average, 20.4% below the 52-week high and +24.8% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does ResMed Inc do?

ResMed makes cloud-connected medical devices for diagnosing and treating sleep and breathing disorders, alongside software for home and residential care providers. Its device range includes portable sleep monitors, remote-monitoring platforms such as AirView, and patient support apps such as myAir. Its software arm, built from brands including Brightree, HealthcareFirst, MatrixCare and MEDIFOX DAN, gives home health, hospice and senior-care organisations tools for records, billing and analytics. Closelook's peer group does not name a comparison set for ResMed; the widely cited rival in sleep and respiratory devices is Koninklijke Philips.

Where does ResMed Inc sit in the AI build-out?

ResMed holds no seat in our AI build-out index; within our wider universe it sits in Healthcare, in the medical instruments and supplies sleeve, covering connected diagnostic devices and care-management software rather than any compute or chip layer. ResMed holds a seat in the S&P 500 but carries no seat in our AI build-out index and no Closelook score; the diary has not yet quoted or covered it in any edition.

Does ResMed Inc pay a dividend?

ResMed Inc has paid 2.46 USD per share over the last twelve months, paid quarterly, a trailing yield of 1.09% on the 2026-09-18 close; the last distribution recorded in the price series was 0.66 USD on 2026-08-20. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on ResMed Inc recently?

The most recent analyst action on ResMed Inc on the Closelook wire is a upgrade by RBC Capital on 2026-09-15 (Sector Perform → Outperform). 2 actions on the analyst wire since 2026-08-13: 1 upgrade, 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for RMD, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Medical Instruments & Supplies. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.